Evaluating side effects of nanoparticle-mediated siRNA delivery to mesenchymal stem cells using next generation sequencing and enrichment analysis

Dominic W. Malcolm¹,² | Janet E. Sorrells¹ | Daniel Van Twisk³ | Juilee Thakar³,⁴ | Danielle S. W. Benoit¹,²,⁵

¹Dept. of Biomedical Engineering, University of Rochester, Rochester, NY 14627
²Center for Musculoskeletal Research, University of Rochester, Rochester, NY 14642
³Dept. of Microbiology and Immunology, University of Rochester, Rochester, NY 14627
⁴Dept. of Biostatistics and Computational Biology, University of Rochester, Rochester, NY 14642
⁵Dept. of Chemical Engineering, University of Rochester, Rochester, NY 14627

Correspondence
Danielle S. W. Benoit, Dept. of Biomedical Engineering, University of Rochester, 207 Robert B. Goergen Hall, Rochester, NY 14627.
Email: benoit@bme.rochester.edu.

Funding Information
Funding for this work came from the National Science Foundation (DMR-1206219), the New York State Stem cell Science program (NYSTEM IDEA-N11G-035), the National Institutes of Health (R01 AR064200, AR056696 and P30 ES001247), and the University of Rochester’s Health Sciences Center for Computational Innovation (HSCCI).

Abstract
RNA interference has immense potential to modulate cell functions. However, effective delivery of small interfering RNA (siRNA) while avoiding deleterious side effects has proven challenging. This study investigates both intended and unintended effects of diblock copolymer nanoparticle (NP) delivery of siRNA delivery to human mesenchymal stem cells (hMSC). Specifically, siRNA delivery was investigated at a range of NP-siRNA:hMSC ratios with a focus on the effects of NP-siRNA treatment on hMSC functions. Additionally, next generation RNA sequencing (RNAseq) was used with enrichment analysis to observe side effects in hMSC gene expression. Results show NP-siRNA delivery is negatively correlated with hMSC density. However, higher NP-siRNA:hMSC ratios increased cytotoxicity and decreased metabolic activity. hMSC proliferation was largely unaffected by NP-siRNA treatment, except for a threefold reduction in hMSCs seeded at 4,000 cells/cm². Flow cytometry reveals that apoptosis is a function of NP-siRNA treatment time and seeding density; ~14% of the treated hMSCs seeded at 8,000 cells/cm² were annexin V⁻siRNA⁻ 24 hr after treatment, while 11% of the treated population was annexin V⁺-siRNA⁺. RNAseq shows that NP-siRNA treatment results in transcriptomic changes in hMSCs, while pathway analysis shows upregulation of apoptosis signaling and downregulation of metabolism, cell cycle, and DNA replication pathways, as corroborated by apoptosis, metabolism, and proliferation assays. Additionally, multiple innate immune signaling pathways such as toll-like receptor, RIG-I-like receptor, and nuclear factor-κB signaling pathways are upregulated. Furthermore, and consistent with traditional siRNA immune activation, cytokine–cytokine receptor signaling was also upregulated. Overall, this study provides insight into NP-siRNA:hMSC ratios that are favorable for siRNA delivery. Moreover, NP-siRNA delivery results in side effects across the hMSC transcriptome that suggest activation of the innate immunity that could alter MSC functions associated with their therapeutic potential.

KEYWORDS
enrichment analysis, mesenchymal stem cells, nanoparticles, off-target effects, RNAi, RNAseq

1 INTRODUCTION

RNA interference (RNAi) is post-transcriptional gene silencing resulting from homologous base pair interaction of double stranded RNA (dsRNA) molecules and target messenger RNA (mRNA). Multiple types of dsRNA, such as microRNA (miRNA) and small interfering RNA (siRNA), can initiate the RNAi pathway, resulting in sequence-specific gene silencing through mechanisms that have been reviewed...
extensively elsewhere. The ability to selectively and efficiently silence specific genes based solely on nucleotide sequence makes RNAi-based drugs promising candidates in myriad applications. This immense therapeutic potential has culminated in over 30 siRNA/ miRNA therapeutic clinical trials as of 2015, with recent studies showing gene knockdown efficacy in humans.

RNAi has recently been recognized as a powerful tool to control tissue-specific cell differentiation. In particular, use of RNAi to affect mesenchymal stem cell (MSC) differentiation has tremendous potential for tissue engineering applications. Over the last decade, many miRNAs have been shown to regulate MSC differentiation. However, translation of RNAi to MSC-based therapeutic strategies has only recently gained traction due to development of safe and versatile delivery systems that match the needs of clinical translation. A comprehensive review shows most studies utilized viral transduction or commercial transfection reagents such as Lipofectamine2000. While these studies have provided promising results, the use of viral vectors are controversial due to the risk of mutagenesis and immunological responses, and the translational potential of commercial transfection reagents is limited due to proprietary chemistries. Due to these problems, several polymeric siRNA delivery systems have been developed. For example, we pioneered the development of a self-assembled diblock copolymer that exhibits excellent gene knockdown in a variety of cells with synthetic versatility to introduce targeting moieties, or, in others work, poly(ethylene glycol) to enhance systemic circulation. Recently, this NP system was shown to modulate gene expression in human mesenchymal stem cells without causing acute cytotoxicity or affecting MSC differentiation capacity.

Despite outstanding progress in the use of RNAi, adverse effects can result in a variety of levels. Gene knockdown can lead to unanticipated changes in downstream signaling cascades, silencing of partially homologous target genes, activation of the innate immune system and delivery system toxicity. A recent study investigated off-target effects of 13 different commercial non-targeting negative control siRNAs from Ambion, Dharmacoon, and Qiagen. Overall, the study concluded that these siRNAs significantly regulate gene expression, and that the extent of differential expression varied among sequences and was cell-type dependent. In the context of RNAi-mediated cell differentiation, understanding off-target effects is especially critical. For example, treatment of MSCs with a commercially available, non-targeting siRNA resulted in adipocyte differentiation in the absence of typical differentiation factors. In addition to RNAi off-target effects, carrier-mediated toxicities have also been well documented and can be manifested through multiple mechanisms including membrane disruption, generation of reactive oxygen species (ROS), or lysosomal overload in the case of non-degradable polymers. These types of side effects can significantly bias conclusions made regarding therapeutic benefit of siRNA delivery.

While our group has shown effective siRNA delivery to hMSCs with no cytotoxicity or alteration in differentiation capacity using polymeric NPs, this approach may alter other critical features of cellular function. Therefore, to more deeply examine the polymer- and siRNA-mediated side effects of siRNA-NP treatment of hMSCs, the objective of this study was twofold: (1) identify treatment conditions that provide for maximal siRNA delivery in hMSCs while maintaining critical cellular functions (e.g., proliferation, metabolic activity, survival), and (2) use next generation sequencing (NGS) to investigate potential side effects via transcriptome-wide changes in gene expression.

2 | RESULTS

2.1 | The effect of cell density on NP-mediated siRNA uptake

Diblock copolymers were synthesized and characterized as previously described (Supporting Information Table S1) and self-assembled via dialysis to produce spherical 43 ± 11 nm NP with narrow particle size distribution (PDI = 0.19) and zeta potential of +19 ± 1 mV when measured in 1× phosphate buffered saline (PBS) (Figure 1A, Supporting Information Table S2). Flow cytometry was used to quantify uptake of fluorescently labeled non-targeting NP-siRNA complexes delivered to hMSCs at multiple cell seeding densities. Figure 1B shows that the number of MSCs positive for NP-siRNA uptake significantly increased as MSC seeding density decreased from 32,000 to 8,000 cells/cm². At 32,000 cells/cm², 22% ± 2% of the cell population was positive for NP-siRNA uptake. This increased to 58% ± 1% at 16,000 cells/cm² and 83% ± 7% at 8,000 cells/cm². The number of siRNA-positive hMSCs increased to 88% ± 4% when seeding density was decreased to 4,000 cells/cm², but this was not statistically significant compared to 8,000 cells/cm². Furthermore, we analyzed median fluorescence intensity (MFI) of the treated MSCs as a measure of the amount of NP-siRNA taken up by treated cells. Figure 1C shows MFI increased as seeding density decreased. Although there was no difference in number of siRNA-positive cells at 4,000 and 8,000 cells/cm², the cells at the lower density exhibited greater overall NP-siRNA uptake. As a positive control, we treated hMSCs seeded at 8,000 cells/cm² with fluorescent siRNA using Lipofectamine2000 (Lipo2000-siRNA), a commercially available delivery system. Figure 1D shows that Lipo2000-siRNA treatment resulted in more siRNA-positive hMSCs and greater MFI compared to our NP delivery system. To corroborate successful NP-siRNA uptake, microscopy was used to visualize siRNA uptake (Figure 1E-H). hMSCs seeded at 8,000 cells/cm² illustrate robust internalization of NP-siRNA (Figure 1H) that appears diffuse throughout the cytoplasm. Interestingly, Lipofectamine2000 also mediated significant siRNA uptake, however, the internalized siRNA was punctate and confined (Figure 1G), suggesting persistence of siRNA in the endo-lysosomal compartments.

2.2 | The effect of hMSC seeding density on NP-siRNA mediated gene silencing

Gene silencing efficiency of NP-siRNA treatment was also investigated as a function of seeding density. NPs were complexed with siRNA targeting housekeeping gene peptidylprolyl isomerase B (PPIB) and incubated with hMSCs for 24 hr. PPIB mRNA expression was measured 48 hr post-treatment. Figure 2A shows NP-siRNA complexes exhibit robust silencing in PPIB expression levels in hMSCs seeded at 4,000
and 8,000 cells/cm² achieving gene knockdown to 28% ± 3% and 43% ± 13% of control PPIB expression; however, these reductions were not statistically different. Furthermore, hMSCs at 16,000 cells/cm² showed PPIB expression of 77% ± 25% relative to untreated controls while gene silencing was attenuated at 32,000 cells/cm².

### 2.3 | hMSC function after NP-siRNA treatments

Immediate cytotoxicity and long-term effects on hMSCs were also examined as a function of NP-siRNA treatment using non-targeting negative control siRNA. As a measure of relative hMSC number, DNA content was quantified and reported relative to untreated controls 24 hr post-treatment. Figure 3A shows NP-siRNA complexes did not cause significant loss in cell viability at densities from 32,000 to 8,000 cells/cm², as evidenced by unchanged DNA content relative to untreated controls. At 4,000 cells/cm², DNA content in NP-siRNA treated hMSCs was significantly reduced to 70% ± 3% compared to untreated hMSCs. Figure 3B shows the NP-siRNA delivery system performed similarly to Lipofectamine2000.

After assessing the immediate effects of NP-siRNA treatments on hMSC survivability, long-term metabolic activity of hMSCs was probed. Figure 3C-F shows metabolic activity for untreated hMSCs and hMSCs treated with NP-siRNA or Lipo2000-siRNA at 4,000 (C), 8,000 (D), 16,000 (E), and 32,000 cells/cm² (F). To compare groups, metabolic rates were extrapolated from linear regions of the metabolic activity data (i.e., the first 7 days, Figure 3G). Analysis revealed NP-siRNA
treated hMSCs seeded at 4,000 and 8,000 cells/cm² showed significantly reduced metabolic rates compared to untreated hMSCs. At 16,000 cells/cm², NP-siRNA treatment did not alter hMSC metabolic rate. Interestingly, at 32,000 cells/cm², NP-siRNA treated hMSCs showed significant, albeit slight, increases in metabolic rate, which could be attributed to slight variability in initial seeding densities. Figure 3F shows the overlaid curves are nearly indistinguishable. Lipo2000-siRNA treated hMSCs exhibited reduced metabolic activity only at 4,000 cells/cm² compared to untreated cells, albeit to a lesser extent than NP-siRNA-treated hMSCs at the same density.

2.4 Effect of NP-siRNA treatment on hMSC proliferation

To better characterize diminished hMSC metabolic activity after NP-siRNA treatment, hMSC proliferation was measured via 5-ethynyl-2’-deoxyuridine (EdU) incorporation. EdU is a nucleoside analog that is incorporated into newly synthesized DNA during cell proliferation. Figure 4 shows that hMSC proliferation was largely unaltered by NP-siRNA treatment with a non-targeting siRNA. However, a threefold reduction in the number of proliferating hMSCs was observed 5 days post-treatment seeded at 4,000 cells/cm². Similar to DNA quantification, these data also show that proliferation is negatively correlated with hMSC seeding density, regardless of NP-siRNA treatment.

2.5 Effect of NP-siRNA treatment on hMSC apoptosis

Annexin V and propidium iodide (PI) staining of hMSCs was used to measure apoptosis. Specifically, analysis of treated hMSCs seeded at 4,000 and 8,000 cells/cm² was performed via flow cytometry, as hMSC metabolism was reduced at these seeding densities (Figure 5A, B). Generally, annexin V staining increased with time post-treatment and was greater for NP-siRNA-treated cells than Lipo2000-siRNA treated cells at both seeding densities. At 4,000 cells/cm², 22% ± 2% and 39% ± 4% of NP-siRNA treated hMSCs were annexin V⁺ at 6 and 24 hr post-treatment. This is significantly increased compared to Lipo2000-siRNA treatment and untreated hMSCs. Annexin V staining was ~50% lower in hMSCs seeded at 8,000 vs. 4,000 cells/cm² in all treatment conditions (Figure 5B). A fluorescently labeled non-targeting siRNA was used to further discriminate annexin V⁺-siRNA⁺ hMSCs. At 4,000 cells/cm² 6 hr post-treatment, only 5% ± 1% of NP-treated hMSCs were annexin V⁺-siRNA⁺, while 18% ± 1% were annexin V⁺-siRNA⁻ (Figure 5C). The number of Lipo2000-siRNA-treated hMSCs were annexin V⁺-siRNA⁺. After 24 hr, the number of annexin V⁺-siRNA⁺ NP-treated hMSCs increased to 20% ± 2% with 16% ± 0.4% that was annexin V⁺-NP-siRNA⁻. The number of Lipo2000-siRNA treated annexin V⁺-siRNA⁺ hMSCs significantly increased to 25% ± 3% without detectable annexin V⁺-Lipo2000-siRNA⁻ cells 24 hr post-treatment (Figure 5C). The same trends were observed at 8,000 cells/cm², but to a lesser extent (Figure 5D). By including PI, a dye impermeable to intact cell membranes, early apoptotic (annexin V⁺-PI⁺) and late apoptotic (annexin V⁺-PI⁻) hMSCs could be detected within the annexin V⁺-siRNA⁺ hMSCs to determine commitment to apoptosis after uptake of siRNA. Figure 5E shows that at 4,000 cells/cm² 6 hr post-treatment, NP-siRNA and Lipo2000-siRNA treatments all resulted in similar amounts of early and late apoptotic siRNA⁺ hMSCs. At 24 hr, these populations increased to 8% ± 3% early and 13% ± 1% late apoptotic for NP-siRNA⁻ hMSCs and 6% ± 0.3% early and 19% ± 2% late apoptotic for Lipo2000-siRNA⁻ hMSCs. At 8,000 cells/cm² 6 hr post-treatment results largely corroborated those at 4,000 cells/cm² (Figure 5F) and there were no significant differences between groups at 24 hr.

2.6 Transcriptome-wide effects of NP-siRNA treatment and gene set enrichment analysis

Beyond uptake, knockdown, metabolism, proliferation, and apoptosis, RNA sequencing (RNAseq) was performed on hMSCs to observe...
FIGURE 3  NP-siRNA treated hMSCs seeded at lower densities showed reduced DNA content 24 hr post-treatment and reduced cellular metabolism that persisted through 14 days post-treatment. Quantification of hMSC DNA content suggested significant reduction in hMSC viability when seeded below 8,000 cells/cm² 24 hr post-treatment (A). At 8,000 cells/cm², the NP system performed similarly to Lipofectamine2000 (B). **p < .01, ****p < .0001 compared to untreated controls determined by one-way ANOVA with Bonferroni’s test for multiple comparisons. Metabolic activity was measured over 14 days in hMSCs that are untreated (●, dashed line), Lipo2000-siRNA treated (●, dotted line), or NP-siRNA treated (●, solid line) seeded at 4,000 (C), 8,000 (D), 16,000 (E), and 32,000 cells/cm² (F). Insets in (E) and (F) show metabolic activity on a smaller scale to better visualize changes in metabolic activity due to treatment. Linear regression was performed in each metabolic activity curve to quantify metabolic activity to compare among groups (G), * represents significantly different than untreated, and # represents significantly different than NP-siRNA. (C–F) are representative plots from one experiment that was repeated in an independent experiment that showed similar trends. *p < .05, **p < .01 compared to the previous time point within a single treatment group using two-way ANOVA with Bonferroni’s test for multiple comparisons; #p < .05 untreated compared to treated at a single time point using two-way ANOVA with Tukey’s test for multiple comparisons. Error bars represent standard deviation. AU = arbitrary units.

| Seeding Density (cells/cm²) | Untreated | NP-siRNA | Lipo2000-siRNA |
|-----------------------------|-----------|-----------|----------------|
| 4,000                       | 0.50±0.03 | 0.06±0.02 | 0.31±0.01      |
| 8,000                       | 0.23±0.02 | 0.16±0.01 | 0.18±0.03      |
| 16,000                      | 0.08±0.02 | 0.09±0.01 | 0.08±0.01      |
| 32,000                      | 0.02±0.01 | 0.04±0.003| 0.02±0.01      |
transcriptome-wide perturbations in gene expression after delivery of non-targeting siRNA. Reads were mapped to the human reference genome (GRCh38.p2), assembled per gene and condensed into FPKM expression values (fragments per kilobase of transcript per million mapped reads), which provides a measure of expression levels for each gene mapped in the hMSC transcriptome. To visualize transcriptomic changes in untreated hMSCs over time, NP-siRNA treated hMSCs over time, and NP-siRNA treated vs. untreated (NT) within each time point, a heatmap was generated showing |log2(fold-change)| using a false discovery rate adjusted p-value of .05. Figure 6 shows time course analyses in treated and untreated hMSCs were nearly identical, except for differences in NP-siRNA treated hMSCs at day 5 (D5) relative to D0. Additionally, when comparing NP-siRNA treated vs. untreated hMSCs within each time point, the most drastic changes occur at D5.

Enrichment analysis was performed on pathways using the DAVID functional annotation tool.26 Figure 7A shows upregulated pathways. By comparing day 0 (D0) samples to untreated hMSCs at days 1, 5, and 14 post-treatment, this analysis reveals pathways that are enriched due to culture conditions alone, such as upregulation of the p53 pathway and ECM-receptor pathways. To specifically probe the effect of NP-siRNA treatment, comparisons were made between treated and untreated hMSCs within each time point. As a result of the NP-siRNA treatment, apoptosis and natural killer cell mediated cytotoxicity pathways were upregulated 1 day post-treatment. At 5 days post-treatment, apoptosis signaling is upregulated in addition to multiple pattern recognition receptor signaling pathways, such as Toll-like (TLR), retinoic acid-inducible gene 1 (RIG-I)-like, and nucleotide-binding oligomerization domain-like receptor pathways. Additionally, several inflammatory pathways are upregulated, including cytokine–cytokine receptor interaction and nuclear factor-κB (NF-κB) signaling pathways. Supporting Information Table S6 shows fold-change expression of multiple signaling molecules from these pathways that are significantly upregulated, such as TLR3, DDX58 (the gene encoding RIG-I protein), NFKB1, NFKB2, and various chemokines, cytokines, and associated receptors. By day 14 post-treatment, apoptosis and immunological pathways such as antigen processing and presentation and allograft rejection pathways are enriched. Figure 7B shows the differentially expressed genes in the upregulated apoptosis pathway, and reveals greater fold-change upregulation of anti-apoptotic genes, such as BIRC3, BCL2L1, and TNFSF10C, compared to upregulation of pro-apoptotic genes, such as TNFRSF10A. Figure 7C shows pathways that are significantly downregulated. Cell cycle and DNA replication pathways exhibited the most robust downregulation as a result of culture conditions, not due to NP-siRNA treatment. Glycine, serine and threonine and nitrogen metabolism pathways were significantly downregulated as a result of NP-siRNA treatment beginning 5 days post-treatment. Note that Supporting Information Table S5 contains the adjusted p-values for these enriched pathways.

3 | DISCUSSION

Outstanding progress has been made in the development of delivery systems for RNAi over the past two decades to unleash its immense therapeutic potential to post-transcriptionally target specific genes.13,27–29 We previously developed pH-responsive diblock copolymers that self-assemble to form nanoparticles (NP) that are capable of successful siRNA delivery to multiple cell types both in vitro and in vivo.15–17,30 Successful gene silencing in MSCs was demonstrated via NP delivery of siRNA without compromising multipotential differentiation capacity.16 However, to use this NP delivery system to affect MSC differentiation, it is necessary to thoroughly characterize potential side effects that may abrogate RNAi-based differentiation signals. Specifically, an extended characterization of how treatment conditions affect NP-mediated siRNA delivery was performed while comprehensively evaluating potential side effects including MSC metabolism, proliferation, apoptosis, and global RNA expression profiles.

A range of seeding densities was examined to identify how NP-siRNA:cell ratios affect siRNA delivery, gene knockdown, and identify potential side effects. Results showed that NP-siRNA delivery was increased at lower seeding densities, likely due to higher NP-siRNA: hMSC ratios (Figure 1B, C). Higher NP-siRNA uptake resulted in more robust gene silencing at lower hMSC seeding densities (Figure 2A). Gene silencing capabilities of Lipofectamine2000, a positive control, and NP delivery at 8,000 cells/cm² were statistically equivalent (Figure

**FIGURE 4** hMSC proliferation was mostly unaltered by NP-siRNA treatment. There were no significant differences in hMSC proliferation 1 day and 14 days post-treatment (A and C, respectively). However, NP-siRNA treatment reduced the number of proliferating hMSCs that were seeded at 4,000 cells/cm² 5 days post-treatment. n = 3 from one experiment for (B, C). ***p < .0001 compared to untreated hMSCs using two-way ANOVA with Bonferroni’s test for multiple comparisons. Error bars represent the standard deviation.
siRNA was more effective in delivering siRNA into hMSCs, even though Lipofectamine2000-siRNA treatment resulted in greater siRNA uptake (Figure 1D). This suggests that NP delivery of siRNA is more effective than Lipofectamine2000, even though the latter resulted in greater siRNA uptake. Although lower seeding densities resulted in greater NP-siRNA uptake and gene silencing, higher NP-siRNA:hMSC ratios negatively affected cell viability. Specifically, DNA content was reduced to 70% compared to untreated cells (Figure 3A). This finding might have important implications when adapting this NP-siRNA delivery system for in vitro applications requiring low hMSC densities.

When examining unintended side effects of siRNA delivery systems, it is common to measure immediate cytotoxicity. For example, poly(ethyleneimine) (PEI) and poly(L-lysine) are typically used for nucleic acid delivery and have well-documented cytotoxicity in multiple cell types. While determining immediate cytotoxicity is necessary, it is equally important to monitor physiological functions in treated cells long term, yet these data are not typically reported. This is critical for applications that require extended culture time beyond initial treatments, including for MSC differentiation. AlamarBlue was used to investigate hMSC metabolic activity over 14 days after NP-siRNA treatment. AlamarBlue is advantageous over other metabolic assays such as 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), as it is non-destructive, allowing for longitudinal measurements across the same cell populations. Results show that NP-siRNA treatment reduces metabolic rates of hMSCs at lower seeding densities (Figure 3C, D, G). Lipo2000-siRNA treatment also resulted in reduced metabolism but to a smaller degree than from NP-siRNA treatment. These data also show that in untreated samples, metabolic rate decreases as cell seeding density increases. This is likely due to sub-confluent levels of cell seeding resulting in greater proliferation. For treated samples, it is unknown if reduced metabolic rate is due to alterations in cell proliferation or delayed cell death. AlamarBlue assays have traditionally been utilized to measure cell proliferation, however, metabolic function in bone marrow-derived stromal cells sometimes does not correlate well with DNA synthesis, which immediately precedes cell division. To probe cell proliferation directly, an EdU assay was used. Results show that 1 day post-treatment, NP-siRNA treatment did not alter hMSC proliferation (Figure 4A); however, NP-siRNA treatment significantly reduced EdU+ hMSCs seeded at 4,000 cells/cm² at 5 days post-treatment compared to untreated controls (Figure 4B). After 14 days, the hMSCs recovered, and there was no difference in the number of EdU+ hMSCs (Figure 4C). These data support AlamarBlue data suggesting that hMSC proliferation is inversely correlated with seeding density, regardless of NP-siRNA treatment. This could directly explain greater NP-siRNA uptake at lower seeding densities (Figure 1B, C), as NP uptake is greater in actively proliferating cells.

2B, even though Lipofectamine2000-siRNA treatment resulted in greater siRNA uptake (Figure 1D). This suggests that NP delivery of siRNA was more efficient than Lipofectamine2000. This could be explained by the observations made regarding the diffuse nature of the NP-mediated siRNA delivery in hMSC cytoplasm compared to the punctate signal observed with Lipofectamine2000 (Figures 1H, G), indicating the Lipofectamine2000-siRNA is confined within endolysosomal compartments.

Although lower seeding densities resulted in greater NP-siRNA uptake and gene silencing, higher NP-siRNA:hMSC ratios negatively affected cell viability. Specifically, DNA content was reduced to 70% compared to untreated cells (Figure 3A). This finding might have important implications when adapting this NP-siRNA delivery system for in vitro applications requiring low hMSC densities.

When examining unintended side effects of siRNA delivery systems, it is common to measure immediate cytotoxicity. For example, poly(ethyleneimine) (PEI) and poly(L-lysine) are typically used for nucleic acid delivery and have well-documented cytotoxicity in multiple cell types. While determining immediate cytotoxicity is necessary, it is equally important to monitor physiological functions in treated cells long term, yet these data are not typically reported. This is critical for applications that require extended culture time beyond initial treatments, including for MSC differentiation. AlamarBlue was used to investigate hMSC metabolic activity over 14 days after NP-siRNA treatment. AlamarBlue is advantageous over other metabolic assays such as 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), as it is non-destructive, allowing for longitudinal measurements across the same cell populations. Results show that NP-siRNA treatment reduces metabolic rates of hMSCs at lower seeding densities (Figure 3C, D, G). Lipo2000-siRNA treatment also resulted in reduced metabolism but to a smaller degree than from NP-siRNA treatment. These data also show that in untreated samples, metabolic rate decreases as cell seeding density increases. This is likely due to sub-confluent levels of cell seeding resulting in greater proliferation. For treated samples, it is unknown if reduced metabolic rate is due to alterations in cell proliferation or delayed cell death. AlamarBlue assays have traditionally been utilized to measure cell proliferation, however, metabolic function in bone marrow-derived stromal cells sometimes does not correlate well with DNA synthesis, which immediately precedes cell division. To probe cell proliferation directly, an EdU assay was used. Results show that 1 day post-treatment, NP-siRNA treatment did not alter hMSC proliferation (Figure 4A); however, NP-siRNA treatment significantly reduced EdU+ hMSCs seeded at 4,000 cells/cm² at 5 days post-treatment compared to untreated controls (Figure 4B). After 14 days, the hMSCs recovered, and there was no difference in the number of EdU+ hMSCs (Figure 4C). These data support AlamarBlue data suggesting that hMSC proliferation is inversely correlated with seeding density, regardless of NP-siRNA treatment. This could directly explain greater NP-siRNA uptake at lower seeding densities (Figure 1B, C), as NP uptake is greater in actively proliferating cells.

It is possible that reduction in proliferation 5 days post-treatment and sustained reduction in metabolic activity could be the result of delayed apoptosis. To investigate this possibility, hMSCs were stained with annexin V and quantified by flow cytometry. Results show that NP-siRNA treatment resulted in greater numbers of apoptotic hMSCs compared to untreated controls. The extent of apoptotic hMSCs was inversely correlated with seeding density, again most likely due to increased NP-siRNA to hMSC ratios (Figure 5A, B), possibly through lysosomal overload, as our polymers are non-degradable over the time course of this experiment. Lipo2000-siRNA treatment also resulted in a significant population of apoptotic hMSCs, although to a lesser extent than NP-siRNA treatment. By performing the analysis
with a fluorescently labeled siRNA, approximately half of the apoptotic cells were also positive for NP-siRNA, which was consistent across all seeding densities (Figure 5D, E), while all of the apoptotic cells treated with Lipo2000 were also siRNA. This suggests that there may be indirect effects of NP-siRNA treatment that triggers apoptosis. It is possible that the NP-siRNA population of apoptotic cells could result from uptake of free/uncomplexed NPs, similar to a PEG-pDMAEMA-based siRNA delivery system where free polymer was observed at charge ratios above neutrality, resulting in increased cytotoxicity. To investigate this possibility, we performed particle-tracking analysis to quantitatively evaluate siRNA:NP ratio. Results show that NP concentration is $1.13 \times 10^{12}$ to $2.09 \times 10^{11}$ NPs/mL (Table S2). Using this data combined with siRNA molecular weight, stoichiometry indicates the siRNA:NP ratio is 64:1 for treatments here, suggesting that, statistically, there are no free NPs in treatments that might cause cytotoxicity. Alternatively, apoptotic cells can initiate apoptosis in neighboring cells, as recently described. Furthermore, the use of PI, a cell impermeable dye, allows for the discrimination of early and late apoptotic cells. Results show that of the apoptotic NP-siRNA hMSCs, a significant portion is early apoptotic. This is significant because extracellular exposure of phosphatidyserines, which are detected by annexin V, can be reversible and precedes commitment of apoptosis, suggesting this population of hMSCs may not ultimately die. Overall, this analysis has shown that only 13% of hMSCs seeded at 4,000 cells/cm² and 8% at 8,000 cells/cm² have committed to apoptosis as a result of NP-siRNA uptake, while 18% of Lipo-siRNA hMSCs at 4,000 cells/cm² were late apoptotic, indicating that Lipo2000-siRNA treatment results in greater overall apoptosis than the NP.

RNAseq and enrichment analysis were performed to observe transcriptome-wide perturbations in gene expression and the resulting physiological pathways that might be altered by NP-siRNA treatment. Results show that apoptosis signaling was the most upregulated pathway due to NP-siRNA 1 day post-treatment (Figure 7A). These data are corroborated by results from the annexin V assay that show a significant apoptotic population of hMSCs 1 day post NP-siRNA treatment (Figure 5B). Interestingly, Figure 7B shows anti-apoptotic genes, such as BIRC3, BCL2L1, and TNFSF10C, are among those most highly upregulated within the apoptosis pathway, suggesting that cells are recovering from an initial stress due to NP-siRNA treatment. Additionally, enrichment analysis reveals significant upregulation of multiple innate immune pathways, such as TLR and RIG-I signaling pathways, both of which are activated by dsRNA molecules. Furthermore this analysis shows upregulation of NF-κB signaling and cytokine-cytokine receptor interaction pathways, both of which are downstream of TLR and RIG-I activation. RNAseq data specifically shows upregulation of TLR3, DDX58 (the gene encoding RIG-I protein), NFKB1, and NFKB2 5 days post-treatment (Table S6). At this same time point, multiple chemokines belonging to the C-X-C motif (CXC) and C-C motif (CC) families and cytokines of the tumor necrosis factor (TNF) and interleukin (IL) families are also significantly altered (Table S6).

Figure 7C shows the most highly downregulated pathways are the cell cycle and DNA replication pathways, but only as a result of culture conditions. This is directly corroborated by EdU results (Figure 4) that indicate hMSC proliferation decreases with time, but was independent of NP-siRNA treatment at 8,000 cells/cm². Furthermore, multiple metabolic pathways (glycine, serine and threonine and nitrogen
metabolism) are downregulated by NP-siRNA treatment, which is in direct agreement with AlamarBlue results in Figure 3 that show a significant reduction in hMSC metabolism as a result of NP-siRNA treatment. It is possible that these effects are a result of immune activation; however, there are conflicting reports on whether immune activation decreases or increases MSC metabolism.

It has been shown that siRNA can activate the innate immune system via TLR3 interactions. TLR3 is expressed in the hMSC endosomal compartment making it possible that endosomal trafficking of NP-siRNA results in TLR signaling. Furthermore, TLR activation in hMSCs has been shown to stimulate secretion of immunomodulatory cytokines and chemokines, such as CCL2, TNF, and multiple...
interleukins.\textsuperscript{51,53} RIG-I signaling, which is associated with the immune response, was activated in MSCs after delivery of a double stranded miRNA-145 mimic using Lipofectamine2000.\textsuperscript{54} This effect was specific to a poly(U) sequence, a dsRNA motif that has been previously shown to activate RIG-I.\textsuperscript{55} The non-targeting siRNA pool used in this study contains four non-targeting siRNAs. Of these, two contain a poly(U) sequence, which could be responsible for upregulation of RIG-I. RIG-I signaling could also be activated as a result of TLR cross-talk.\textsuperscript{56} Irrespective of pathway, TLR activation has been shown to affect MSC differentiation in a TLR-specific manner. Activation of TLR3 via poly(I:C), a dsRNA analogue, inhibited osteogenic differentiation, while activation of TLR4 via lipopolysaccharide enhanced osteogenic differentiation.\textsuperscript{57}

Taken together, these results suggest that our NP-siRNA delivery system may be activating MSC innate immunity at multiple levels: in the endosome where TLR3 receptor is localized when the NPs are endocytosed, and in the cytosol where RIG-I is located after NP-mediated endosomal escape of the siRNA. Alterations in this signaling may affect MSC differentiation, although previous work from our lab has shown that siRNA delivery with very similar polymer NPs did not alter MSC adiopogenesis, osteogenesis, or chondrogenesis.\textsuperscript{16}

To our knowledge, this is the first study probing long term, temporal side effects of nanoparticle-mediated siRNA delivery in MSCs. Overall, the side effects observed here are consistent with those traditionally associated with siRNA delivery.\textsuperscript{5,20} Furthermore, based on our results, we hypothesize that the use of pH-responsive polymers for siRNA delivery has the potential to activate the innate immunity at multiple levels via activation of endosomal TLRs and cytosolic RIG-I-like receptors. This analysis gives insight into potential side effects of NP-siRNA delivery, but is limited by convolution of NP and siRNA effects. Separating these effects is especially challenging when using cationic carriers because without shielding by anionic cargo, the delivery system has much different physiochemical properties that can confer unique cellular responses. For example, a previous study has shown that the chain length of poly(dimethylaminoethyl methacrylate) (pDMAEMA), the cationic constituent of the diblock copolymers used here, modulates the mechanism of cytotoxicity from membrane disruption to induction of apoptosis, while the amount of cationic charge influenced the extent and kinetics of endocytosis and intracellular trafficking.\textsuperscript{58} Additionally, in the aforementioned study involving Lipofectamine2000-mediated delivery of miRNA-145 in MSCs, treatment with Lipofectamine2000 alone induced an immune response that was unique vs. a negative control siRNA and miRNA-145.\textsuperscript{59} Unfortunately, use of alternative anionic molecules in place of siRNA has the potential to introduce additional off-target effects. This, coupled with the fact that naked siRNA cannot be internalized by cells renders NP-only and siRNA-only controls inappropriate for this work.

3.1 | Conclusions

Overall, NP-siRNA:hMSC ratios have been identified for siRNA delivery while undertaking an extensive characterization of side effects due to NP-siRNA delivery. An inverse correlation exists between NP-siRNA uptake and function with hMSC seeding density, while high NP-siRNA:hMSC ratios can result in cytotoxicity. Furthermore, the importance of monitoring cellular function for extended periods beyond initial treatment is highlighted, as sustained changes in cellular function were observed. Further, NP-siRNA treatment resulted in a significant portion of annexin V expressing hMSCs that may not be committing to apoptosis. RNAseq and pathway enrichment analysis similarly suggested alterations in hMSC metabolism and proliferation and suggest activation of the innate immune system via TLR and RIG-I signaling, which could also contribute to apoptosis and changes in metabolism and proliferation. Moreover, this study shows that new technologies, such as NGS coupled with enrichment analysis are powerful tools for identifying potential side effects, which is necessary for safe translation of therapeutic systems from the bench to the clinic.

4 | MATERIALS AND METHODS

4.1 | Polymer and nanoparticle synthesis and characterization

Please refer to “Supporting Information.”

4.2 | hMSC culture

hMSCs were isolated from human bone marrow isolates (Lonza),\textsuperscript{60} and cultured in growth media composed of low glucose Dulbecco’s Modified Eagle’s Medium (Gibco) with 10% fetal bovine serum (Atlanta Biologics), 1% antibiotic-antimycotic (Gibco) and 1 ng/mL recombinant human basic fibroblast growth factor-2 (Corning) and kept at 37°C with 5% CO\textsubscript{2}. hMSCs were used at passage 3–5.

4.3 | Preparation of NP-siRNA treatments

NP-siRNA treatments were prepared at 10× the final treatment concentration of 30 nM siRNA at a charge ratio = 4 (+/−) and added directly to cell culture media, as previously described.\textsuperscript{16} Please refer to “Supporting Information” for description of charge ratio. All untreated samples were given an equal treatment volume of 1× PBS. Where indicated, Lipofectamine 2000 (Invitrogen) was used as a positive control according to the manufacturer’s protocol at 30 nM siRNA. All siRNA product numbers and sequences, if available, are listed in Supporting Information Table S3.

4.4 | Quantification of NP-uptake via flow cytometry

hMSCs were seeded at 4,000 cells/cm\textsuperscript{2} in 6 well plates and at 8,000, 16,000, and 32,000 cells/cm\textsuperscript{2} in 12-well plates. Larger plates were used for lower seeding densities to increase overall cell number. NPs were complexed with Silencer FAM-labeled Negative Control No. 1 siRNA (Ambion) as previously described. After 24 hr incubation, hMSC were washed 3× with 1× PBS, trypsinized and transferred to 1.5 mL tubes and washed once more. hMSCs were resuspended in 100 μL flow buffer (0.5 w/v% bovine serum albumin, and 0.01 v/v% trypan blue to quench extracellular fluorescence)\textsuperscript{61} Samples were analyzed on...
an Accuri C6 flow cytometer. Propidium Iodide (PI, Molecular Probes) was added to each sample (1:500) immediately prior to analysis for discrimination of dead cells. 2,000 hMSC events were gated for analysis. Single stained samples were used for compensation and data was analyzed using FlowJo software.

4.5 | Microscopy

hMSCs were seeded on Nunc Lab-Tek II chamber slides (Thermo Scientific) at 8,000 cells/cm² and treated as described previously for flow cytometry. After 24 hr, cells were fixed in 4% paraformaldehyde and mounted with ProLong Gold Antifade Mountant with DAPI (4′,6-diamidino-2-phenylindole, Invitrogen). Phase and fluorescence images were obtained using a Nikon Eclipse Ti2000 inverted microscope.

4.6 | Assessing NP-mediated gene knockdown

hMSCs were seeded at 4,000 cells/cm² in 6 well plates and at 8,000, 16,000, and 32,000 cells/cm² in 12-well plates and treated with NPs complexed with siRNA targeting PPIB. After 24 hr, media was replaced and hMSCs were incubated for an additional 24 hr. After 48 hr post-treatment, RNA was purified using Homogenizer mini-columns and E.Z. N.A. total RNA Kit I with on-column DNase digestion (Omega Bio-tek) according to the manufacturer’s protocol. Isolated RNA was quantified and quality was monitored using a NanoVue (GE Healthcare). All 260/280 values were greater than 1.8, indicating high purity RNA. RNA concentration among triplicate samples was normalized, and then reverse transcribed using iScript cDNA Synthesis Kit (Bio-Rad) according to the manufacturer’s protocol. cDNA was diluted to 1 ng/µL RNA equivalence. 2 µL of diluted cDNA was used in each qRT-PCR reaction. qRT-PCR was performed using Sso-Fast EvaGreen Supermix (Bio-Rad) on a CFX96 Real-time PCR detection System (Bio-Rad). Forward and reverse primers were used at 500 nM (sequences are listed in Table S4). qRT-PCR cycling parameters were as follows: hold at 95°C for 5 min for enzyme activation, then 40 cycles of 95°C for 5 s. denaturing, 55°C (GAPDH) or 60°C (PPIB) for 60 s. annealing, and 72°C for 20 s. extension. Primer efficiencies were calculated from each well as previously described⁶² using 3 and 6% of the maximum amplification to set two thresholds. Relative expression was calculated using the Pfaffl equation relative to untreated samples and normalized to GAPDH expression.⁶³

4.7 | Relative quantification of hMSC DNA content

hMSCs were treated with NPs complexed to ON-TARGETplus Non-targeting Control Pool siRNA (Dharmacon) as described previously. 24 hr later, cells were washed twice with 1× PBS and lysed using 1× Luciferase Cell Culture Lysis reagent (Promega) in 1× PBS. Lysates were sonicated for 10 s using a probe sonicator. 10 µL of cell lysates were diluted in 90 µL 1× TE buffer and DNA content was quantified using Quant-iT PicoGreen dsDNA Assay Kit (Invitrogen) according to the manufacturer’s protocol.

4.8 | Effect of NP-siRNA treatment on hMSC metabolic activity

Metabolic activity was assessed in treated hMSCs using Alamar Blue Cell Viability Reagent (Molecular Probes) as previously described.¹⁴ Metabolic activity was normalized to Day 0 samples that were taken immediately before NP-siRNA treatments were applied.

4.9 | Quantification of hMSC proliferation after NP-siRNA treatment

Treated hMSC proliferation was measured using Click-iT Plus EdU Alexa Fluor 647 Flow Cytometry Assay Kit (Molecular Probes). hMSCs were incubated with 50 µM EdU for 4 hr and staining and detection was carried out according to the manufacturer’s protocol. Samples were analyzed on an Accuri C6 flow cytometer. It should be noted that no FAM-siRNA signal was detectable, in any treated sample, indicating the FAM label may have been compromised during the EdU staining or detection. 5,000–10,000 hMSC events were gated, and FlowJo software was used for analysis.

4.10 | Quantification of hMSC apoptosis after NP-siRNA treatment

hMSCs were treated as described in “Quantification of NP-uptake via flow cytometry.” At 6 and 24 hr post-treatment, hMSC were washed twice with 1× PBS and the presence of phosphatidylserine residues was detected using an Annexin V Alexa Fluor 647 conjugate (Molecular Probes) according to the manufacturer’s protocol. Positive controls for apoptosis were prepared by incubating hMSCs for 20 min at 55°C. PI (Molecular Probes) was added to each sample (1:500 dilution) immediately prior to analysis to enable discrimination of early and late apoptotic cells. Samples were analyzed on an Accuri C6 flow cytometer. 5,000–10,000 hMSC events were gated, and FlowJo software was used for analysis. Single stained samples were used for compensation and fluorescence minus one controls were used to establish gate boundaries.

4.11 | Stranded mRNA seq and NGS processing and alignment

hMSCs were seeded at 8,000 cells/cm² in 6 well plates and incubated for 24 hr with NPs complexed with ON-TARGETplus Non-targeting Control Pool siRNA (Dharmacon) as described in “Preparation of NP-siRNA treatments.” RNA was purified as described in “Assessing NP-mediated gene knockdown” and submitted to the University of Rochester Medical Center’s UR Genomics Research Center. RNA concentration was determined with the NanoDrop 1000 spectrophotometer (NanoDrop) and RNA quality was assessed with the Agilent Bioanalyzer (Agilent). Illumina compatible library construction was performed using the TruSeq Stranded mRNA Sample Preparation Kit (Illumina) according to manufacturer’s protocols. Briefly, mRNA was purified from 100 ng total RNA with oligo-dT magnetic beads and chemically fragmented. First-strand cDNA synthesis was performed using random hexamer priming followed by second-strand cDNA synthesis using dUTP. End
repair and 3’ adenylation was performed on the double stranded cDNA. Illumina adaptors were ligated to both ends of the cDNA, purified by gel electrophoresis and amplified with PCR primers specific to the adaptor sequences to generate amplicons of approximately 200–500 bp in size. The amplified libraries were hybridized to the Illumina single end flow cell and amplified using the cBot (Illumina) at a concentration of 8 pM per lane. Single end reads of 100 nt were generated for each sample and aligned to the human reference genome (GRCh38.p2). Raw reads were generated from an Illumina HiSeq2500 sequencer, and all sequencing data discussed in this publication have been deposited in NCBI’s Gene Expression Omnibus (GEO)64. All files are accessible through GEO Series accession number GSE87497 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE87497).

4.12 Differential expression and pathway analysis

Raw counts were normalized using fragments per kilobase of transcript per million (FPKM). FPKM values less than 10 across all replicated and conditions were removed from further analysis. Differential expression analysis on FPKM normalized counts was performed using Cufflinks version 2.0.2 with the gencode 23 human gene annotations.65 Analysis on FPKM normalized counts was performed using Cufflinks version 2.0.2 with the gencode 23 human gene annotations.65

Enrichment analysis was performed to identify signaling pathways enriched in the differentially expressed genes DAVID functional annotation tool.26 All heat-maps were plotted using the function “heatmap.2” from the R package gplots.66 Adjustment of p-values is performed by Benjamini-Hochberg wherever indicated. All analysis was performed in R.67

4.13 Statistical analysis

Each experiment was performed in triplicate in two independent experiments unless otherwise indicated. One- or two-way ANOVA was used with the appropriate post hoc test as indicated to assess significant differences in means (α = 0.05). Statistical analyses were performed using Prism 6.0 unless otherwise indicated. For all plots, the mean is represented with standard deviation shown as error bars.

ACKNOWLEDGMENTS

The authors would like to thank the University of Rochester Genomics Research Center for RNAseq, the University of Rochester Medical Center’s Flow Cytometry Core for valuable guidance with training and analysis, and Dr. James McGrath for facilities use.

CONFLICT OF INTERESTS

The authors have no conflicts of interest related to this work.

LITERATURE CITED

[1] Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell. 2009;136(4):642–655.
[2] Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15(8):509–524.
[3] Wilson RC, Doudna JA. Molecular mechanisms of RNA interference. Annu Rev Biophys. 2013;42:217–239.
[4] Lam JK, Chow MY, Zhang Y, Leung SW. siRNA versus miRNA as therapeutics for gene silencing. Mol Ther Nucleic Acids. 2015;4:e252.
[5] Wittrup A, Lieberman J. Knocking down disease: a progress report on siRNA therapeutics. Nat Rev Genet. Genet. 2015;16(9):543–552.
[6] Dong S, Yang B, Guo H, Kang F. MicroRNAs regulate osteogenesis and chondrogenesis. Biochem Biophys Res Commun. 2012;418(4):587–591.
[7] Gao J, Yang T, Han J, et al. MicroRNA expression during osteogenic differentiation of human multipotent mesenchymal stromal cells from bone marrow. J Cell Biochem. 2011;112(7):1844–1856.
[8] Guo L, Zhao RC, Wu Y. The role of microRNAs in self-renewal and differentiation of mesenchymal stem cells. Exp Hematol. 2011;39(6):608–616.
[9] Nguyen MK, Jeon O, Krebs MD, Schapira D, Alsbeg E. Sustained localized presentation of RNA interfering molecules from in situ forming hydrogels to guide stem cell osteogenic differentiation. Biomaterials. 2012;33(24):6278–6286.
[10] Yau WWY, Rujitanaroj P-O, Lam L, Chew SY. Directing stem cell fate by controlled RNA interference. Biomaterials. 2012;33(9):2608–2628.
[11] Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 2003;4(5):346–358.
[12] Bessis N, GarciaCozar FJ, Boissier MC. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther. 2004;11(suppl1):S10–S17.
[13] Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8(2):129–138.
[14] Wang J, Lu Z, Wientjes MG, Au JL. Delivery of siRNA therapeutics: barriers and carriers. AAPS J. 2010;12(4):492–503.
[15] Convertine AJ, Benoit DS, Duvall CL, Hoffman AS, Stayton PS. Development of a novel endosomolytic diblock copolymer for siRNA delivery. J Control Release. 2009;133(3):221–229.
[16] Benoit DSW, Boutin ME. Controlling mesenchymal stem cell gene expression using polymer-mediated delivery of siRNA. Biomacromolecules. 2012;13(11):3841–3849.
[17] Arany S, Benoit DS, Dewhurst S, Ovitt CE. Nanoparticle-mediated gene silencing confers radioprotection to salivary glands in vivo. Mol Ther. 2013;21(6):1182–1194.
[18] Benoit DS, Srinivasan S, Shubit AD, Stayton PS. Synthesis of folate-functionalized RAFT polymers for targeted siRNA delivery. Biomacromolecules. 2011;12(7):2708–2714.
[19] Nelson CE, Kintzing JR, Hanna A, Shannon JM, Gupta MK, Duvall CL. Balancing cationic and hydrophobic content of PEGylated siRNA polyplexes enhances endosome escape, stability, blood circulation time, and bioactivity in vivo. ACS Nano. 2013;7(10):8870–8880.
[20] Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov. 2010;9(1):57–67.
[21] Baum P, Fundel-Clemens K, Kreuz S, et al. Off-target analysis of control siRNA molecules reveals important differences in the cytokine profile and inflammation response of human fibroblasts. Oligonucleotides. 2010;20(1):17–26.
[22] Xu Y, Mirmalek-Sani SH, Lin F, Zhang J, Orefo RO. Adipocyte differentiation induced using nonspecific siRNA controls in cultured human mesenchymal stem cells. RNA. 2007;13(8):1179–1183.
[23] Xue HY, Liu S, Wong HL. Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine. Nanomedicine. 2014;9(2):295–312.
[24] Lv H, Zhang S, Wang B, Cui S, Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release. 2006;114(1):100–109.

[25] Akhtar S. Cationic nanosystems for the delivery of small interfering ribonucleic acid therapeutics: a focus on toxicogenomics. Expert Opin Drug Metab Toxicol. 2010;6(11):1347–1362.

[26] Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57.

[27] Kesharwani P, Gajbhiye V, Jain NK. A review of nanocarriers for the delivery of small interfering RNA. Biomaterials. 2012;33(29):7138–7150.

[28] Joo MK, Yhee JY, Kim SH, Kim K. The potential and advances in RNAi therapy: chemical and structural modifications of siRNA molecules and use of biocompatible nanocarriers. J Control Release. 2014;193:113–121.

[29] Gandhi NS, Tekade RK, Chougule MB. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. J Control Release. 2014;184:238–256.

[30] Benoit DS, Henry SM, Shubin AD, Ho ffel S, Aigner A. Polyethylenimines for siRNA and miRNA delivery with polyethylenimines. Adv Genet. 2012;9:20.

[31] Wang YK, Yu X, Cohen DM, et al. Bone morphogenetic protein-2-induced signaling and osteogenesis is regulated by cell shape, RhoA/ROCK, and cytoskeletal tension. Stem Cells Dev. 2012;21(7):1176–1186.

[32] McBeath R, Pirone DM, Nelson CM, Bhadriraju K, Chen CS. Cell shape, cytoskeletal tension, and RhoA regulate stem cell lineage commitment. Dev. Cell. 2004;6(4):483–495.

[33] Neuberg P, Kichler A. Recent developments in nucleic acid delivery. J Control Release. 2010;140(2):140–159.

[34] Liu T, Xue W, Ke B, Xie MQ, Ma D. Star-shaped cyclodextrin-poly-(l-lysine) derivative co-delivering docetaxel and MMP-9 siRNA plasmid in vivo. J Control Release. 2014;184:238–256.

[35] Hobel S, Aigner A. Polyethyleneimines for siRNA and miRNA delivery in vivo. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013;5(5):484–501.

[36] Nimesh S. Polyethyleneimine as a promising vector for targeted siRNA delivery. Curr Clin Pharmacol. 2012;7(2):121–130.

[37] Liu T, Xue W, Ke B, Xie MQ, Ma D. Star-shaped cyclodextrin-poly(l-lysine) derivative co-delivering docetaxel and MMP-9 siRNA plasmid in cancer therapy. Biomaterials. 2014;35(12):3865–3872.

[38] Guo J, Cheng WP, Yu J, et al. Systemic delivery of therapeutic small interfering RNA using a pH-activated amphiphilic poly-L-lysine nanocarrier to suppress prostate cancer growth in mice. Eur J Pharm Sci. 2012;45(5):521–532.

[39] Hunter AC. Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicity. Adv Drug Deliv Rev. 2006;58(14):1523–1531.

[40] Rampersad SN. Multiple applications of Alamar Blue as an indicator of metabolic function and cellular health in cell viability bioassays. Sensors (Basel). 2012;12(9):12347–12360.

[41] Quent VM, Loessner D, Friis T, Reichert JC, Hutmacher DW. Discrepancies between metabolic activity and DNA content as tool to assess cell proliferation in cancer research. J Cell Mol Med. 2010;14(4):1003–1013.

[42] Kim JA, Aberg C, Salvati A, Dawson KA. Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population. Nat Nanotechnol. 2012;7(1):62–68.

[43] Stern ST, Adisesiah PA, Crist RM. Autophagy and lysosomal dysfunction as emerging mechanisms of nanomaterial toxicity. Part Fibre Toxicol. 2012;9:20.

[44] Gary DJ, Min J, Kim Y, Park K, Won YY. The effect of N/P ratio on the in vitro and in vivo interaction properties of PEGylated poly(2-(dimethylamino)ethyl methacrylate)-based siRNA complexes. Macromol. Biosci. 2013;13(8):1059–1071.

[45] Perez-Garjio A, Fuchs Y, Steller H. Apoptotic cells can induce non-autonomous apoptosis through the TNF pathway. Elife. 2013;2:e01004.

[46] Hammill AK, Uhr JW, Scheuermann RH. Annexin V staining due to loss of membrane asymmetry can be reversible and precede commitment to apoptotic death. Exp Cell Res. 1999;251(1):16–21.

[47] Kawai T, Akira S. TLR signaling. Cell Death Differ. 2006;13(5):816–825.

[48] Loo YM, Gale M Jr. Immune signaling by RIG-I-like receptors. Immunity. 2011;34(4):680–692.

[49] Bayram M, Shew NY, Chong KY, Ng E, et al. Liposome delivery of miRNA-145 to metastatic cancer cells, and use of biocompatible nanocarriers. J Control Release. 2012;9:20.

[50] Matsumoto M, Funami K, Tatematsu M, Azuma M, Seya T. Annexin V staining due to background to polycation induced cytotoxicity. Adv Drug Deliv Rev. 2006;58(14):1523–1531.

[51] Tomchuck SL, Zweedaryk J, Hoffman AS, Stayton PS. pH-responsive polymeric sima carriers sensitize multidrug resistant ovarian cancer cells to doxorubicin via knockdown of polo-like kinase 1. Mol Pharm. 2010;7(2):442–455.

[52] Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57.

[53] Akhtar S. Cationic nanosystems for the delivery of small interfering ribonucleic acid therapeutics: a focus on toxicogenomics. Expert Opin Drug Metab Toxicol. 2010;6(11):1347–1362.

[54] Joo MK, Yhee JY, Kim SH, Kim K. The potential and advances in RNAi therapy: chemical and structural modifications of siRNA molecules and use of biocompatible nanocarriers. J Control Release. 2014;193:113–121.

[55] Gandhi NS, Tekade RK, Chougule MB. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. J Control Release. 2014;184:238–256.

[56] Benoit DS, Henry SM, Shubin AD, Ho ffel S, Aigner A. Polyethylenimines for siRNA and miRNA delivery with polyethylenimines. Adv Genet. 2012;48:263–288.

[57] Hobel S, Aigner A. Polyethyleneimines for siRNA and miRNA delivery in vivo. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013;5(5):484–501.

[58] Nimesh S. Polyethyleneimine as a promising vector for targeted siRNA delivery. Curr Clin Pharmacol. 2012;7(2):121–130.

[59] Liu T, Xue W, Ke B, Xie MQ, Ma D. Star-shaped cyclodextrin-poly(l-lysine) derivative co-delivering docetaxel and MMP-9 siRNA plasmid in cancer therapy. Biomaterials. 2014;35(12):3865–3872.

[60] Guo J, Cheng WP, Yu J, et al. Systemic delivery of therapeutic small interfering RNA using a pH-activated amphiphilic poly-L-lysine nanocarrier to suppress prostate cancer growth in mice. Eur J Pharm Sci. 2012;45(5):521–532.
[62] Liu W, Saint DA. A new quantitative method of real time reverse transcription polymerase chain reaction assay based on simulation of polymerase chain reaction kinetics. Anal Biochem. 2002;302(1): 52–59.

[63] Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic acids Res. 2001;29(9):e45.

[64] Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic acids research. 2002;30(1):207–210.

[65] Trapnell C, Roberts A, Goff L, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc. 2012;7(3):562–578.

[66] gplots: Various R programming tools for plotting data. R package version 2.17.0 [computer program]; 2015.

[67] R: a language and environment for statistical computing. [computer program]. Vienna, Austria: R Foundation for Statistical Computing; 2015.

SUPPORTING INFORMATION

Additional Supporting Information may be found in the online version of this article.

FIGURE S1 Critical charge ratio (CR) is determined via gel electrophoresis by loading varying NP:siRNA ratios at different theoretical charge ratios. Critical charge ratio is the CR at which the free siRNA band is absent, indicating complete complexation with NP. (A) Image obtained after running and staining gel under illumination from a UV table. (B) Lane intensity plots produced in ImageJ. Bright bands are represented as negative peaks. (C) Band intensities from Image J and subsequent % siRNA complexation defined as the 100-(band intensity/free siRNA band intensity*100). ND = not detectable

TABLE S1 Polymer characterization. Verified by GPC1, Verified by NMR2

TABLE S2 NP characterization

TABLE S3 siRNAs used in analysis herein

TABLE S4 Primer sequences used in this study

TABLE S5 p-values adjusted using Benjamini-Hochberg method depicting pathways enriched in upregulated and downregulated genes. See supplementary spreadsheet, “Supplemental_Table_S5.xlsx”

TABLE S6 Differentially regulated genes involved in innate immune signaling pathways from RNAseq analysis listing official gene symbol, chromosomal locus, log2(fold-change) of NP-siRNA treated vs. untreated (NT) and FDR adjusted p-value. * = no detectable expression in untreated samples. Italics indicate gene encoding a receptor